Axogen, Inc.
AXGNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Axogen, Inc. (AXGN) is listed under Medical Devices. The $2.23B market capitalization puts AXGN squarely in mid-cap range for its industry. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Market Cap
$2.23B
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
52.43
EPS (TTM)
$-0.67
EPS (Fwd)
$0.73
ROE
-18.2%
ROA
-3.1%
Cash
$111.4M
Total Debt
$20.1M
Free CF
$18.2M
52W Change
109.5%
Annual Financials
Cash vs Debt
Where AXGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AXGN finished 14.71% below its 150-day moving average ($41.32) and 9.99% below its 200-day moving average ($39.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AXGN overbought or oversold?
At the October 20, 2026 close, AXGN's RSI(14) was 19.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $111.4M in cash comfortably exceeding the $20.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $18.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -18.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $127.4M (2021) to $225.2M (2025), reflecting a 77% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AXGN.